Centogene
Centogene to Sell Business to Private Equity Group for €8.7M, Liquidate Remaining Subsidiaries
Charme Capital Partners will acquire complete ownership of Centogene GmbH and will assume Centogene's loan from Oxford Finance.
Nasdaq to Delist Centogene
The German firm did not appeal the decision and will be delisted after having failed to achieve certain milestones to retain its status as a listed company.
Centogene Delisted From Nasdaq
The German rare disease company expects its common stock to begin trading on the OTC Markets Group platform on Aug. 8 under the ticker symbol CNTGF.
In Brief This Week: Roche; IVDR; Thermo Fisher Scientific; Centogene; ACCC; More
News items for the week of May 27, 2024.
Centogene 2023 Revenues up 2 Percent, Firm Secures $20M in Funding
The German disease company said the growth is primarily driven by diagnostics revenues, especially in whole-exome and whole-genome sequencing tests.
Jan 19, 2024
In Brief This Week: DermTech, Centogene, Devyser
Apr 28, 2023
Centogene Receives Nasdaq Noncompliance Notice
Dec 19, 2022